TMEM167B-DT

Across TCGA pan-cancer cohorts, TMEM167B-DT RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated TMEM167B-DT data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TMEM167B-DT RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM167B-DT expression acts as an unfavorable survival marker, although some lineages such as PAAD and MESO show a favorable association.

BLCA, PAAD, and UCEC are the cancer types where TMEM167B-DT RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	III,IV	0.257	0.517	<.001	126	view →
PAAD	OS	Tertile	All	0.595	0.360	.002	48	view →
UCEC	DFS	Median	All	0.789	0.885	<.001	36	view →
MESO	DFS	Median	IV	0.503	0.145	<.001	21	view →
SARC	DFS	Quartile	All	0.658	0.441	.002	18	view →
ACC	OS	Quartile	All	1.000	0.763	.024	14	view →
UCS	OS	Median	IV	0.224	0.732	.018	12	view →
KIRP	DFS	Quartile	IV	0.033	0.529	.006	12	view →
PRAD	DFS	Median	All	0.919	0.847	.009	12	view →
STAD	DFS	Quartile	II,III,IV	0.798	0.554	.020	9	view →
KICH	OS	Median	III,IV	0.426	0.907	.015	8	view →
SKCM	OS	Tertile	IV	0.896	0.513	.032	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

TMEM167B-DT–BLCA (OS)

Open the BLCA breakdown →